At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
nab-sirolimus +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label Study of ABI-009 (Nab-Rapamycin) in Patients With Recurrent High-grade Glioma and Patients With Newly Diagnosed Glioblastoma
In Brief
A Phase 2 clinical trial evaluating nab-sirolimus, nab-sirolimus + temozolomide, and 4 other interventions for High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma. Completed, enrolled 62 participants across 3 sites.
Detailed Summary
Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma. nab-Sirolimus was administered as single agent or in combination therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartAug 2018
Primary CompletionAug 2022
TodayJul 2026
First PostedMar 13, 2018
Enrollment StartAug 1, 2018
Primary CompletionAug 26, 2022
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 8.3 years ago
Interventions
nab-sirolimusdrug
nab-sirolimus, single agent
nab-sirolimus + temozolomidedrug
temozolomide, combination
nab-sirolimus + bevacizumabdrug
bevacizumab, combination
nab-sirolimus + lomustinedrug
lomustine, combination
nab-sirolimus + marizomib (MRZ)drug
marizomib (MRZ), combination
nab-sirolimus + temozolomide + radiotherapydrug
temozolomide + radiotherapy, combination